

**Wanbury Limited**

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
Fax : +91-22-6794 2111/333
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

June 27, 2025

BSE Limited PJ. Towers, Dalal Street Mumbai – 400 001. Script Code: 524212	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051. Script Code: WANBURY
---	--

Dear Sir/Madam,

Sub: Press Release

Please find attached a Press Release with titled “Wanbury Ltd. Launches Iron Supplement ‘Wanbury C RED’ to Combat Anemia with Superior Safety and Absorption”

This is for your information and record.

Thanking you.

Yours faithfully,
For Wanbury Ltd



Jitendra J. Gandhi
Company Secretary



Wanbury Ltd. Launches Iron Supplement ‘Wanbury C RED’ to Combat Anemia with Superior Safety and Absorption

***Marks an impressive debut in North & South India with strong clinician / doctors support
Resulting in substantial early uptake"***



26th June, 2025, MUMBAI: Wanbury Limited, a leading pharmaceutical company with a good legacy in domestic branded formulations and global API markets, proudly announces the successful regional launch of **Wanbury C RED**, a next-generation Liposomal Iron formulation mainly designed to revolutionize anemia management in India.

This novel formulation leverages liposomal technology, which ensures enhanced absorption, minimal metallic aftertaste, reduced risk of constipation, and no calcium chelation thus making it a safe and highly tolerable option for long-term use, especially in pregnant women and iron-deficient individuals.

The product was recently launched in Northern India followed by Southern India has already garnered tremendous response from clinicians/doctors. With many healthcare professionals (doctors) expressing confidence in prescribing the product it has resulted in an impressive early sales performance. Encouraged by the initial success, Wanbury aims to scale up distribution Pan-India in the first few months of the launch.

Commenting on the performance, Mr. Mohan Rayana, Director of Wanbury Ltd., said,

*“The strong debut of **Wanbury C RED** and the encouraging endorsement from clinicians/doctors in the North & South zone give us the confidence to accelerate our nationwide expansion. With robust sales momentum, our Pan-India rollout is already in motion. We believe **Wanbury C RED** will play a significant role in reinforcing Wanbury’s presence in key therapeutic areas while driving both reach and profitability in the domestic formulations market.”*

Wanbury C RED steps into the shoes of its earlier successful brand, C Pink, which was divested to Cipla Limited a few years ago. With **Wanbury C RED**, the company reasserts its leadership in the gynaecology segment.

India’s iron supplement market is witnessing steady growth, driven by the high prevalence of anemia, which continues to affect over 40% of the population. In response to this urgent need, Wanbury has introduced **Wanbury C RED**, a superior iron supplement that ensures rapid haemoglobin rise with significantly fewer gastrointestinal side effects, a common drawback in conventional iron therapies.

About Wanbury Ltd.

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine, Ketamine Hydrochloride and various other products in pipeline. The company's clients include some of the leading global generic players.

In formulations, the company has a wide presence across major therapeutic categories like, cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastro intestinal, anti-inflammatory, & analgesics.

For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For further information please contact

Jitendra J. Gandhi

Company Secretary,

Wanbury Limited

BSEL Techpark, B' Wing, 10th Floor,
Sector 30-A, Opp. Vashi Railway Station,
Vashi, Navi Mumbai - 400703, India.

Tel: +91-22-6794 2222

Email: jitendra.gandhi@wanbury.com

Hanishi Shah / Anand Venugopal

Adfactors PR

Oasis Complex, Kamala Mills Compound, City Hall,
Pandurang Budhkar Marg, Lower Parel West,
Mumbai – 400021

Tel: +91 9619059339 / +91 7021852071

Email: hanishi.shah@adfactorspr.com

anand.venugopal@adfactorspr.com

Disclaimer:

This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.

